ClinicalTrials.Veeva

Menu

Study of the Anti-tumoral Immune Response (ERISA)

C

Centre Hospitalier Universitaire de Besancon

Status

Completed

Conditions

Breast Cancer
Glioma

Treatments

Other: additional blood sample

Study type

Interventional

Funder types

Other

Identifiers

NCT02854644
P/2013/188

Details and patient eligibility

About

This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.

Enrollment

167 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Performance status 0,1 or 2
  • breast cancer or glioma
  • Arm glioma: patients without anti-tumoral treatment
  • Arm breast cancer: inclusion before treatment
  • Arm breast cancer HER2: patients with current therapy

Exclusion criteria

  • Psychiatric disease compromising the understanding of the information or the realization of the study
  • vulnerable People according to the law (minors, adults under protection, private persons of freedom ...)
  • Unaffiliated People to the Social Security
  • People being for the period of exclusion from another study
  • Life expectancy estimated unless 3 months.
  • For patients in Arm glioma: patients having already begun a systematic treatment.
  • For patients with a breast cancer: patient already under current therapy

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

167 participants in 4 patient groups

glioma
Experimental group
Description:
1 additional blood sample for patients with glioma and without treatment
Treatment:
Other: additional blood sample
breast cancer
Experimental group
Description:
2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
Treatment:
Other: additional blood sample
breast cancer HER2+
Experimental group
Description:
1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
Treatment:
Other: additional blood sample
Breast Cancer HER 2+ or HER2 triple -
Experimental group
Description:
1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
Treatment:
Other: additional blood sample

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems